ArticleMedicine2026
An analysis of digoxin serum concentrations and influencing factors: A cross-sectional study from a tertiary hospital in China.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The digoxin drug has a narrow therapeutic window that requires regular blood concentration monitoring in a tertiary hospital. The concentration of a drug varies due to several factors. The factors may include physiological and biochemical factors, comorbidities, and concomitant medications. The purpose of this study was to analyze the monitoring data of serum digoxin concentration (SDC) using logistic regression and to find the SDC correlated factors. SDC with a cutoff value of 0.9 ng/mL, which corresponds to the proposed safety upper limit by international heart failure recommendations (ACCF/AHA). This cross-sectional study retrospectively analyzed data from 178 patients at Jiande First People's Hospital, including SDC, demographic characteristics, biochemical parameters, comorbidities, and medication use. Patients were stratified into 2 groups based on an SDC cutoff of 0.9 ng/mL (<0.9 vs ≥0.9 ng/mL) to describe population characteristics and perform comparative analyses, including univariate logistic regression. Variables with P < .1 in the univariate analysis were included in a stepwise regression model. Factors with P < .05 which remained in the final model. Among 178 patients, those with SDC < 0.9 ng/mL accounted for 43.26%, while patients with SDC ≥ 0.9 ng/ml comprised 56.74%. The median SDC was 1.05 ng/ml (IQR: 0.54, 1.60). Univariate analysis revealed several factors significantly associated with SDC levels. The results of multivariate logistic regression indicated that age (odds ratio [OR] = 1.10, 95% confidence interval [CI]: 1.05-1.15, P < .001), chloride ion (Cl-) (OR = 0.87, 95% CI: 0.81-0.94, P < .001), high-density lipoprotein cholesterol (HDLC) (OR = 0.08, 95% CI: 0.02-0.30, P < .001), blood urea nitrogen (BUN) (OR = 1.15, 95% CI: 1.07-1.25, P < .001), Deslanoside (OR = 5.41, 95% CI: 1.39-21.15, P = .015), and hypoglycemic drugs (OR = 0.30, 95% CI: 0.10-0.89, P = .030) were all significantly associated with SDC levels. Age, Cl-, HDLC, BUN, Deslanoside, and hypoglycemic drugs are independent factors influencing SDC. These findings provide valuable references for the rational clinical use of digoxin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.